We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current ZYME market cap is 630.17M. The company's latest EPS is USD -1.6817 and P/E is -3.82.
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 35.58M | 7M | 16.51M | 17.22M | 10.03M |
Operating Income | -27.28M | -54.11M | -33.24M | -9.17M | -37.8M |
Net Income | -24.35M | -51.15M | -28.69M | -14.48M | -31.65M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 29.54M | 38.95M | 26.68M | 412.48M | 76.3M |
Operating Income | -150.53M | -187.47M | -215.63M | 130.53M | -137.76M |
Net Income | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M |
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 600.74M | 602.05M | 556.37M | 580.88M | 553.75M |
Total Liabilities | 127.21M | 153.14M | 132.02M | 116.07M | 115.75M |
Total Equity | 473.54M | 448.92M | 424.34M | 464.81M | 438M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 368.21M | 538.38M | 389.13M | 648.73M | 580.88M |
Total Liabilities | 122.52M | 128.45M | 140.04M | 155.77M | 116.07M |
Total Equity | 245.68M | 409.92M | 249.09M | 492.96M | 464.81M |
Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -83.19M | -89.59M | -132.26M | -118.3M | -37.67M |
Investing | -138.22M | -198.9M | -205.92M | -207.25M | -7.32M |
Financing | 1.74M | 29.34M | 31.24M | 81.85M | 2.12M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -81.85M | -151.4M | -192.45M | 144.11M | -118.3M |
Investing | -25.59M | -43.44M | 144.6M | -53.85M | -207.25M |
Financing | 193.66M | 308.98M | 8.01M | 108.58M | 81.85M |
Market Cap | 630.17M |
Price to Earnings Ratio | -3.82 |
Price to Sales Ratio | 5.95 |
Price to Cash Ratio | 2.88 |
Price to Book Ratio | 0.98 |
Dividend Yield | - |
Shares Outstanding | 70.57M |
Average Volume (1 week) | 527.65k |
Average Volume (1 Month) | 699.21k |
52 Week Change | -8.88% |
52 Week High | 13.14 |
52 Week Low | 6.015 |
Spread (Intraday) | 0.04 (0.45%) |
Company Name | Zymeworks Inc |
Address |
595 burrard street north vancouver, british columbia V7X 1L3 |
Website | https://www.zymeworks.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions